Astellas' JAK inhibitor meets Phase IIa psoriasis endpoint

Astellas Pharma Inc. (Tokyo:4503) said oral JAK inhibitor ASP015K met the primary endpoint of significantly improving Psoriasis Area and Severity Index (PASI) score from baseline to day 42 vs. placebo...